Arcturus Therapeutics is developing a portfolio of nucleic acid therapeutics for treatment of diseases with high unmet medical needs. Our hope and vision is to build transformative, life-changing medicines for patients and their families.
Our team has extensive experience in the discovery and development of RNA medicines, as well as design and utilization of lipid-mediated drug delivery systems. This combination of in-house expertise, innovative spirit, and passion for what we do, uniquely positions us to catalyze the next generation of nucleic medicines.
September 21, 2018
Arcturus Therapeutics Expands Management Team
August 29, 2018
Arcturus Therapeutics Announces Appointment of Ernst & Young LLP as the Company’s Independent Auditor
August 28, 2018
Arcturus Therapeutics Appoints Andrew Sassine as Interim Chief Financial Officer